Medical Science News

RSS

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, today announced initial results from a Phase I multicenter safety study of PDA-001 in treatment-resistant Crohn's Disease. PDA-001 is an immunomodulatory therapy consisting of human placenta-derived cells obtained from CCT's proprietary processes.

9 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

Raised levels of carbon dioxide in blood may lead to ‘near death experiences’

Near death experiences (NDEs), reported to include sensations such as life flashing before the eyes, feelings of peace and joy, and apparent encounters with mystical entities, may be caused by raised levels of carbon dioxide in the blood. Researchers writing in BioMed Central's open access journal Critical Care investigated the unexplained events in 52 cardiac arrest patients.

8 Apr 2010

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Oncolytics Biotech Inc. announced today that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin Harrington of the Institute of Cancer Research, London, UK, was published in the online version of the Journal of Clinical Investigation on April 1, 2010.

8 Apr 2010

UBC doctoral candidate discovers a mechanism for silencing retroviruses

A University of British Columbia doctoral candidate has discovered a previously unknown mechanism for silencing retroviruses, segments of genetic material that can lead to fatal mutations in a cell's DNA.

8 Apr 2010

Potential toxicity of zinc nanoparticles in sunscreen products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death. Their study is in ACS' Chemical Research in Toxicology, a monthly journal.

8 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company has completed enrollment of all subjects for its therapeutic cervical cancer vaccine (VGX-3100) phase I trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18, and is delivered via in vivo electroporation.

8 Apr 2010

Molecular gauge helps examine working of new drugs when they bind to DNA or RNA

Luminescent markers are an indispensable tool for researchers working with DNA. But the markers are troublesome. Some tend to destroy the function and structure of DNA when inserted. Others emit so little light, that they can barely be detected in the hereditary material. So researchers have been asking for alternative markers.

8 Apr 2010

Scientific evidence links high levels of copper and iron to age-related disorders

With scientific evidence linking high levels of copper and iron to Alzheimer's disease, heart disease, and other age-related disorders, a new report in ACS' Chemical Research in Toxicology suggests specific steps that older consumers can take to avoid build up of unhealthy amounts of these metals in their bodies.

8 Apr 2010

Role of beta defensins in development of chronic inflammatory response in the brain

Researchers at the Case Western Reserve University School of Dental Medicine and School of Medicine will look for evidence within the brain for human beta defensin peptide function-proteins important to the peripheral body's natural defense system against infection from the outside environment.

8 Apr 2010

Researchers identify major indicator of heart failure and aortic aneurysms

Case Western Reserve University School of Medicine researchers have identified a major indicator of two deadly diseases of the heart and blood vessels: heart failure and aortic aneurysm. The absence of the Kruppel-like Factor 15, when combined with stress, leads to both heart failure and aortic aneurysms.

8 Apr 2010

USPTO allows Alnylam Pharmaceuticals' new claims from Woppmann et al. patent series

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent Office (USPTO) has allowed a patent (Application No. 10/560,336) for the Woppmann et al. patent series, entitled "Double-stranded ribonucleic acid with increased effectiveness in an organism." The newly allowed patent includes 31 claims broadly covering compositions and methods, including pharmaceutical compositions, for small interfering RNAs (siRNAs), the molecules that mediate RNAi.

8 Apr 2010

Roche NimbleGen to implement GMP for DNA microarrays suite

Roche NimbleGen, announced today a company-wide initiative to implement Good Manufacturing Processes (GMP) for its suite of DNA microarrays. The implementation of GMP will cover the full scope of processes from development through manufacturing and will include all locations. The company plans on achieving GMP compliance followed by subsequent submission for clearance or approval of select array products to the US Food and Drug Administration.

8 Apr 2010

First proton therapy center for New Jersey

Cancer survivors joined representatives from ProCure Treatment Centers, Inc., Princeton Radiation Oncology, and CentraState Healthcare System to break ground on the ProCure Proton Therapy Center in Somerset - the first proton therapy center to be built in the state, located 40 miles from downtown Manhattan.

8 Apr 2010

Researchers find new genomic approach to identify smokers at risk of lung cancer

Researchers from Boston University School of Medicine in collaboration with investigators at the University of Utah, have discovered a new approach for identifying smokers at the highest risk for developing lung cancer. The findings, which appear in the April 7th issue of Science Translational Medicine, will allow the researchers to use a genomic approach to prevent lung cancer in these individuals and to personalize cancer chemoprophylaxis and therapy.

8 Apr 2010

Charter Medical introduces Bio-Pak Cell Culture bags

Charter Medical, Ltd., a division of Lydall, Inc., today announced the launch of Bio-Pak® Cell Culture bags for biotech and pharmaceutical processing. These bags are designed to provide a stable cell culture environment to enhance cell growth and viability. They are made from Charter's high performance Clear-Pak® film, a single web, multi-layer film with superior gas barrier properties.

8 Apr 2010

Nutritional supplement can increase blood circulation of hematopoietic stem cells

A nutritional supplement could stimulate the production of stem cells integral for repairing the body. Research published in BioMed Central's open access Journal of Translational Medicine suggests that a commercially-available supplement can increase the blood circulation of hematopoietic stem cells, which can give rise to all blood cells, and endothelial progenitor cells, which repair damage to blood vessels.

8 Apr 2010

Pair of proteins excreted in urine could lead to earlier diagnosis of kidney cancer: Researchers

Studying patients with kidney cancer, a team of researchers at Washington University School of Medicine in St. Louis has identified a pair of proteins excreted in the urine that could lead to earlier and more accurate diagnosis of the disease.

8 Apr 2010

Medical Science News

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Raised levels of carbon dioxide in blood may lead to ‘near death experiences’

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

UBC doctoral candidate discovers a mechanism for silencing retroviruses

Potential toxicity of zinc nanoparticles in sunscreen products

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Molecular gauge helps examine working of new drugs when they bind to DNA or RNA

Scientific evidence links high levels of copper and iron to age-related disorders

Role of beta defensins in development of chronic inflammatory response in the brain

Researchers identify major indicator of heart failure and aortic aneurysms

USPTO allows Alnylam Pharmaceuticals' new claims from Woppmann et al. patent series

Roche NimbleGen to implement GMP for DNA microarrays suite

First proton therapy center for New Jersey

Researchers find new genomic approach to identify smokers at risk of lung cancer

Charter Medical introduces Bio-Pak Cell Culture bags

Nutritional supplement can increase blood circulation of hematopoietic stem cells

Pair of proteins excreted in urine could lead to earlier diagnosis of kidney cancer: Researchers

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News